{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:15:19Z","timestamp":1792239319007,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Winn Career Development Award"},{"name":"NIH-NCI Cancer Center Support Grant","award":["P30 CA016059"],"award-info":[{"award-number":["P30 CA016059"]}]},{"name":"NIH-NCI Cancer Center Support Grant","award":["P30 CA016059"],"award-info":[{"award-number":["P30 CA016059"]}]},{"name":"NIH-NCI Cancer Center Support Grant","award":["P30 CA016059"],"award-info":[{"award-number":["P30 CA016059"]}]},{"name":"NIH-NCI Cancer Center Support Grant","award":["P30 CA016059"],"award-info":[{"award-number":["P30 CA016059"]}]},{"name":"NIH: ETCTN","award":["UM1CA186644"],"award-info":[{"award-number":["UM1CA186644"]}]},{"name":"NIH: ETCTN","award":["UM1CA186644"],"award-info":[{"award-number":["UM1CA186644"]}]},{"name":"NIH: ETCTN","award":["UM1CA186644"],"award-info":[{"award-number":["UM1CA186644"]}]},{"name":"NIH: ETCTN","award":["UM1CA186644"],"award-info":[{"award-number":["UM1CA186644"]}]},{"name":"NIH: ETCTN","award":["UM1CA186644"],"award-info":[{"award-number":["UM1CA186644"]}]},{"name":"NIH: ETCTN","award":["UM1CA186644"],"award-info":[{"award-number":["UM1CA186644"]}]},{"name":"NIH","award":["P30CA006973"],"award-info":[{"award-number":["P30CA006973"]}]},{"name":"NIH","award":["P30CA006973"],"award-info":[{"award-number":["P30CA006973"]}]},{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Shared Instrument Grant","award":["S10OD020091"],"award-info":[{"award-number":["S10OD020091"]}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR003098"],"award-info":[{"award-number":["UL1TR003098"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["R6508-18"],"award-info":[{"award-number":["R6508-18"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Relapsed and\/or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome continue to have a poor prognosis with limited treatment options despite advancements in rational combination and targeted therapies. Belinostat (an HDAC inhibitor) and Pevonedistat (a NEDD8 inhibitor) have each been independently studied in hematologic malignancies and have tolerable safety profiles with limited single-agent activity. Preclinical studies in AML cell lines and primary AML cells show the combination to be highly synergistic, particularly in high-risk phenotypes such as p53 mutant and FLT-3-ITD positive cells. Here, we present the safety, pharmacokinetics and pharmacodynamics of belinostat and pevonedistat in a dose escalation Phase I study in AML and High-Risk MDS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Eighteen patients (16 with AML, 2 with MDS) were treated at 5 dose levels (belinostat 800\u20131000\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , pevonedistat 20\u201350\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ). Safety and tolerability were assessed according to protocol defined dose limiting toxicities (DLTs). Correlative pharmacokinetic and pharmacodynamic analyses were performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No dose limiting toxicities were noted. Most Grade 3 or 4 toxicities were hematologic in nature. The best response was stable disease in four patients, and complete remission in one patient who qualified as an exceptional responder. Pharmakokinetic studies revealed no association between drug exposure and best response. Pharmacodynamic RT-PCR studies demonstrated post-treatment increases in several proteins, including quantitative increases in the oxidative stress protein NQO1, ferroptosis protein SLC7A11, and GSR, linked to glutathione metabolism and oxidative stress, as did the anti-oxidants SRXN1 and TXNRD1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patterns of post-treatment changes in correlative pharmacodynamic parameters may suggest possible mechanistic changes in the DNA damage response, oxidative damage, and ferroptosis pathways. The combination of pevonedistat plus belinosat is safe in an adult relapsed and\/or refractory AML\/High-Risk MDS population with modest but notable activity in this heavily treated, high risk population. Our findings also raise the possibility that certain extremely poor prognosis AML patients may respond to a regimen combining two targeted agents that have little or no activity when administered individually.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov ID NCT03772925, first posted 12\/12\/2018; CTEP Identifier 10246.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00280-024-04742-9","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:45:34Z","timestamp":1737074734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A phase I study of MLN4924 and belinostat in relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome"],"prefix":"10.1007","volume":"95","clinical-trial-number":[{"clinical-trial-number":"nct03772925","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Keri R.","family":"Maher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Schaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipankar","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Piekarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Rudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Donald","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"4742_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100996","volume":"57","author":"IM Bouligny","year":"2023","unstructured":"Bouligny IM, Maher KR, Grant S (2023) Mechanisms of myeloid leukemogenesis: current perspectives and therapeutic objectives. Blood Rev 57:100996","journal-title":"Blood Rev"},{"issue":"12","key":"4742_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"issue":"3","key":"4742_CR3","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/j.bbmt.2018.12.407","volume":"25","author":"R Nath","year":"2019","unstructured":"Nath R, Reddy V, Kapur A, Gebregergish S, Gurskyte L, Kulakova M et al (2019) Survival of relapsed\/refractory acute myeloid leukemia (R\/R AML) patients receiving stem cell transplantation (SCT). Biol Blood Marrow Transplant 25(3):S125","journal-title":"Biol Blood Marrow Transplant"},{"key":"4742_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.649209","volume":"11","author":"ME Tenold","year":"2021","unstructured":"Tenold ME, Moskoff BN, Benjamin DJ, Hoeg RT, Rosenberg AS, Abedi M et al (2021) Outcomes of adults with relapsed\/refractory acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a comprehensive cancer center. Front Oncol 11:649209","journal-title":"Front Oncol"},{"issue":"9","key":"4742_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1182\/blood.2019001982","volume":"136","author":"S DeWolf","year":"2020","unstructured":"DeWolf S, Tallman MS (2020) How I treat relapsed or refractory AML. Blood 136(9):1023\u20131032","journal-title":"Blood"},{"issue":"23","key":"4742_CR6","doi-asserted-by":"publisher","first-page":"6149","DOI":"10.1128\/MCB.01481-08","volume":"29","author":"S Chen","year":"2009","unstructured":"Chen S, Dai Y, Pei X-Y, Grant S (2009) Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-x<sub>L<\/sub>, and Mcl-1. Mol Cell Biol 29(23):6149\u20136169","journal-title":"Mol Cell Biol"},{"issue":"2","key":"4742_CR7","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1182\/blood-2002-12-3794","volume":"102","author":"JL Aron","year":"2003","unstructured":"Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME et al (2003) Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 102(2):652\u2013658","journal-title":"Blood"},{"issue":"13","key":"4742_CR8","first-page":"3637","volume":"63","author":"RR Rosato","year":"2003","unstructured":"Rosato RR, Almenara JA, Grant S (2003) The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1\/WAF1 1. Cancer Res 63(13):3637\u20133645","journal-title":"Cancer Res"},{"issue":"7336","key":"4742_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nature09803","volume":"471","author":"T Robert","year":"2011","unstructured":"Robert T, Vanoli F, Chiolo I, Shubassi G, Bernstein KA, Rothstein R et al (2011) HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 471(7336):74\u201379","journal-title":"Nature"},{"issue":"1","key":"4742_CR10","first-page":"51","volume":"5","author":"F Carrier","year":"2013","unstructured":"Carrier F (2013) Chromatin modulation by histone deacetylase inhibitors: impact on cellular sensitivity to ionizing radiation. Mol Cell Pharmacol 5(1):51\u201359","journal-title":"Mol Cell Pharmacol"},{"issue":"3","key":"4742_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1073\/pnas.0408732102","volume":"102","author":"JS Ungerstedt","year":"2005","unstructured":"Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G et al (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102(3):673\u2013678","journal-title":"Proc Natl Acad Sci USA"},{"issue":"33","key":"4742_CR12","doi-asserted-by":"publisher","first-page":"14639","DOI":"10.1073\/pnas.1008522107","volume":"107","author":"JH Lee","year":"2010","unstructured":"Lee JH, Choy ML, Ngo L, Foster SS, Marks PA (2010) Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 107(33):14639\u201314644","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"4742_CR13","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O'Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J et al (2015) Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 33(23):2492\u20132499","journal-title":"J Clin Oncol"},{"issue":"10","key":"4742_CR14","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.3109\/10428194.2013.877134","volume":"55","author":"MH Kirschbaum","year":"2014","unstructured":"Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B, Tuscano JM et al (2014) A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma 55(10):2301\u20132304","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"4742_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00277-011-1240-1","volume":"91","author":"A Cashen","year":"2012","unstructured":"Cashen A, Juckett M, Jumonville A, Litzow M, Flynn PJ, Eckardt J et al (2012) Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Ann Hematol 91(1):33\u201338","journal-title":"Ann Hematol"},{"issue":"2","key":"4742_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10637-014-0194-2","volume":"33","author":"O Odenike","year":"2015","unstructured":"Odenike O, Halpern A, Godley LA, Madzo J, Karrison T, Green M et al (2015) A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs 33(2):371\u2013379","journal-title":"Invest New Drugs"},{"issue":"21","key":"4742_CR17","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1182\/blood.V118.21.2598.2598","volume":"118","author":"B Holkova","year":"2011","unstructured":"Holkova B, Tombes MB, Shrader E, Cooke SS, Wan W, Sankala H et al (2011) Phase I trial of belinostat and bortezomib in patients with relapsed or refractory acute leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia in blast crisis. Blood 118(21):2598","journal-title":"Blood"},{"issue":"7239","key":"4742_CR18","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature07884","volume":"458","author":"TA Soucy","year":"2009","unstructured":"Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S et al (2009) An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458(7239):732\u2013736","journal-title":"Nature"},{"issue":"18","key":"4742_CR19","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1182\/blood-2009-11-254862","volume":"115","author":"RT Swords","year":"2010","unstructured":"Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E et al (2010) Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 115(18):3796\u20133800","journal-title":"Blood"},{"issue":"9","key":"4742_CR20","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","volume":"116","author":"MA Milhollen","year":"2010","unstructured":"Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L et al (2010) MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-\u03baB\u2013dependent lymphoma. Blood 116(9):1515\u20131523","journal-title":"Blood"},{"issue":"13","key":"4742_CR21","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1158\/1078-0432.CCR-12-3212","volume":"19","author":"ST Nawrocki","year":"2013","unstructured":"Nawrocki ST, Kelly KR, Smith PG, Espitia CM, Possemato A, Beausoleil SA et al (2013) Disrupting protein NEDDylation with MLN4924 Is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res 19(13):3577\u20133590","journal-title":"Clin Cancer Res"},{"issue":"13","key":"4742_CR22","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1158\/0008-5472.CAN-12-0388","volume":"72","author":"Z Luo","year":"2012","unstructured":"Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D et al (2012) The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Can Res 72(13):3360\u20133371","journal-title":"Can Res"},{"issue":"4","key":"4742_CR23","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bjh.13323","volume":"169","author":"RT Swords","year":"2015","unstructured":"Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M et al (2015) Pevonedistat (MLN4924), a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Br J Haematol 169(4):534\u2013543","journal-title":"Br J Haematol"},{"issue":"17","key":"4742_CR24","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","volume":"6","author":"L Ad\u00e8s","year":"2022","unstructured":"Ad\u00e8s L, Girshova L, Doronin VA, D\u00edez-Campelo M, Valc\u00e1rcel D, Kambhampati S et al (2022) Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Adv 6(17):5132\u20135145","journal-title":"Blood Adv"},{"issue":"25","key":"4742_CR25","doi-asserted-by":"publisher","first-page":"16220","DOI":"10.1073\/pnas.252462599","volume":"99","author":"ML Guzman","year":"2002","unstructured":"Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ et al (2002) Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 99(25):16220\u201316225","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"4742_CR26","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1182\/blood-2009-11-254862","volume":"115","author":"RT Swords","year":"2010","unstructured":"Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E et al (2010) Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 115(18):3796\u20133800","journal-title":"Blood"},{"issue":"17","key":"4742_CR27","doi-asserted-by":"publisher","first-page":"11446","DOI":"10.1074\/jbc.M809394200","volume":"284","author":"MA Glozak","year":"2009","unstructured":"Glozak MA, Seto E (2009) Acetylation\/deacetylation modulates the stability of DNA replication licensing factor Cdt1 *. J Biol Chem 284(17):11446\u201311453","journal-title":"J Biol Chem"},{"issue":"1","key":"4742_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1158\/0008-5472.CAN-12-1729","volume":"73","author":"JL Blank","year":"2013","unstructured":"Blank JL, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H et al (2013) Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. Cancer Res 73(1):225\u2013234","journal-title":"Cancer Res"},{"issue":"12","key":"4742_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014335","volume":"5","author":"W Brazelle","year":"2010","unstructured":"Brazelle W, Kreahling JM, Gemmer J, Ma Y, Cress WD, Haura E et al (2010) Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One 5(12):e14335","journal-title":"PLoS One"},{"issue":"18","key":"4742_CR30","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1182\/blood-2015-06-653717","volume":"127","author":"L Zhou","year":"2016","unstructured":"Zhou L, Chen S, Zhang Y, Kmieciak M, Leng Y, Li L et al (2016) The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Blood 127(18):2219\u20132230","journal-title":"Blood"},{"issue":"4","key":"4742_CR31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447","journal-title":"Blood"},{"issue":"1","key":"4742_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/1078-0432.CCR-15-1237","volume":"22","author":"JJ Shah","year":"2016","unstructured":"Shah JJ, Jakubowiak AJ, O\u2019Connor OA, Orlowski RZ, Harvey RD, Smith MR et al (2016) Phase I Study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed\/refractory multiple myeloma or lymphoma. Clin Cancer Res 22(1):34\u201343","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4742_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00280-023-04511-0","volume":"91","author":"D Shafer","year":"2023","unstructured":"Shafer D, Kagan AB, Rudek MA, Kmieciak M, Tombes MB, Shrader E et al (2023) Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies. Cancer Chemother Pharmacol 91(3):281\u2013290","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"4742_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0145-2126(00)00127-2","volume":"25","author":"S Ito","year":"2001","unstructured":"Ito S, Ishida Y, Murai K, Kuriya S (2001) Flow cytometric analysis of aberrant antigen expression of blasts using CD45 blast gating for minimal residual disease in acute leukemia and high-risk myelodysplastic syndrome. Leuk Res 25(3):205\u2013211","journal-title":"Leuk Res"},{"issue":"2","key":"4742_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1615\/CritRevEukarGeneExpr.v22.i2.40","volume":"22","author":"H Harada","year":"2012","unstructured":"Harada H, Grant S (2012) Targeting the regulatory machinery of BIM for cancer therapy. Crit Rev Eukaryot Gene Expr 22(2):117\u2013129","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"8","key":"4742_CR36","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula P, Zhuang L, Gan B (2021) Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell 12(8):599\u2013620","journal-title":"Protein Cell"},{"issue":"9","key":"4742_CR37","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1080\/15548627.2020.1810918","volume":"17","author":"X Chen","year":"2021","unstructured":"Chen X, Li J, Kang R, Klionsky DJ, Tang D (2021) Ferroptosis: machinery and regulation. Autophagy 17(9):2054\u20132081","journal-title":"Autophagy"},{"issue":"23","key":"4742_CR38","doi-asserted-by":"publisher","first-page":"11408","DOI":"10.1073\/pnas.1903244116","volume":"116","author":"MR McLoughlin","year":"2019","unstructured":"McLoughlin MR, Orlicky DJ, Prigge JR, Krishna P, Talago EA, Cavigli IR et al (2019) TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy. Proc Natl Acad Sci 116(23):11408\u201311417","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"4742_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12885-021-07782-z","volume":"21","author":"J Fraisse","year":"2021","unstructured":"Fraisse J, Dinart D, Tosi D, Bellera C, Mollevi C (2021) Optimal biological dose: a systematic review in cancer phase I clinical trials. BMC Cancer 21(1):60","journal-title":"BMC Cancer"},{"issue":"9","key":"4742_CR40","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nsmb.1899","volume":"17","author":"KM Miller","year":"2010","unstructured":"Miller KM, Tjeertes JV, Coates J, Legube G, Polo SE, Britton S et al (2010) Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 17(9):1144\u20131151","journal-title":"Nat Struct Mol Biol"},{"issue":"17","key":"4742_CR41","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1093\/nar\/gkn550","volume":"36","author":"A Kinner","year":"2008","unstructured":"Kinner A, Wu W, Staudt C, Iliakis G (2008) Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36(17):5678\u20135694","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"4742_CR42","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1007\/s10637-022-01286-8","volume":"40","author":"X Zhou","year":"2022","unstructured":"Zhou X, Vaishampayan U, Mahalingam D, Harvey RD, Chung KY, Sedarati F et al (2022) Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. Invest New Drugs 40(5):1042\u20131050","journal-title":"Invest New Drugs"},{"issue":"11","key":"4742_CR43","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1111\/bcp.14078","volume":"85","author":"HM Faessel","year":"2019","unstructured":"Faessel HM, Mould DR, Zhou X, Faller DV, Sedarati F, Venkatakrishnan K (2019) Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies. Br J Clin Pharmacol 85(11):2568\u20132579","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"4742_CR44","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nchembio.1313","volume":"9","author":"P Magnaghi","year":"2013","unstructured":"Magnaghi P, D\u2019Alessio R, Valsasina B, Avanzi N, Rizzi S, Asa D et al (2013) Covalent and allosteric inhibitors of the ATPase VCP\/p97 induce cancer cell death. Nat Chem Biol 9(9):548\u2013556","journal-title":"Nat Chem Biol"},{"issue":"2","key":"4742_CR45","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nm.4474","volume":"24","author":"ML Hyer","year":"2018","unstructured":"Hyer ML, Milhollen MA, Ciavarri J, Fleming P, Traore T, Sappal D et al (2018) A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nat Med 24(2):186\u2013193","journal-title":"Nat Med"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04742-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04742-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04742-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T01:22:21Z","timestamp":1737076941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04742-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4742"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04742-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4889008\/v1","asserted-by":"object"}]},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"NCI Central IRB served as the IRB or Record for this study. All patients provided signed informed consent prior to participation in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"24"}}